| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
4-Hydroxyhippuric acid does not have a specific molecular target but functions as a metabolite and potential biomarker. As a by-product of polyphenol metabolism, it reflects the activity of the gut microbiota. It is a human serum metabolite and is associated with various health conditions, including uremia and eosinophilic esophagitis. Its function is related to N-benzoylglycine, and it is the conjugate acid of p-hydroxyhippurate. Its role as a metabolite makes it a valuable tool for studying metabolic pathways and clinical biomarkers.
|
|---|---|
| ln Vitro |
In vitro, 4-Hydroxyhippuric acid is used as a reference standard and in studies of polyphenol metabolism. It is a by-product of polyphenol degradation and can be detected in human serum and urine. It increases microbiota activity associated with refeeding. The compound's activity is related to its role as a metabolite rather than a pharmacologically active compound. Its concentrations can be measured by HPLC or LC-MS/MS in biological samples. It is a potential indicator in metabolic and clinical biomarker studies.
|
| ln Vivo |
In vivo, 4-Hydroxyhippuric acid is a human serum metabolite that is associated with various health conditions. It is a by-product of polyphenol metabolism and reflects the activity of the gut microbiota. Its levels in serum and urine are associated with uremia, eosinophilic esophagitis, and other health conditions. It serves as a potential biomarker for metabolic and clinical studies. The compound is not used as a therapeutic agent but as a research tool for studying metabolism and disease biomarkers.
|
| Enzyme Assay |
The in vitro assays for 4-Hydroxyhippuric acid typically involve analytical chemistry methods such as HPLC or LC-MS/MS for quantification in biological samples. The compound is extracted from serum, urine, or tissue homogenates using solid-phase extraction or protein precipitation. Chromatographic separation is performed using a C18 column with a mobile phase of acetonitrile and water containing 0.1% formic acid. Detection is performed using UV absorbance or mass spectrometry. Calibration curves are prepared using known concentrations of the compound. Quality control samples are included in each analytical run.
|
| Cell Assay |
For in vitro cellular assays, 4-Hydroxyhippuric acid is not typically used as a pharmacologically active compound. It may be used in studies of polyphenol metabolism, where cells (e.g., intestinal epithelial cells) are treated with polyphenols, and the production of 4-hydroxyhippuric acid is measured by LC-MS/MS. The compound may also be used as a reference standard in biomarker studies. Cell viability is assessed using MTT or CellTiter-Glo assays. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo studies, 4-Hydroxyhippuric acid is not administered to animals as a therapeutic agent. It is measured as a biomarker in serum or urine samples from animal models of metabolic diseases, uremia, or eosinophilic esophagitis. The compound's levels are correlated with disease progression or treatment response. Sample preparation and analysis are performed using HPLC or LC-MS/MS. All animal procedures are conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 4-Hydroxyhippuric acid are not relevant, as it is a metabolite rather than a therapeutic agent. The compound has a molecular weight of 195.17 and is a small, polar molecule. It is produced as a by-product of polyphenol metabolism and is excreted in urine. Its levels in biological fluids reflect the activity of the gut microbiota and polyphenol consumption. Comprehensive PK data are not available in publicly accessible literature.
|
| Toxicity/Toxicokinetics |
The toxicology of 4-Hydroxyhippuric acid is not relevant, as it is a metabolite rather than a therapeutic agent. At physiological concentrations, it is considered non-toxic. The compound is associated with health conditions such as uremia and eosinophilic esophagitis, but these associations are related to disease states rather than direct toxicity of the compound itself. Standard laboratory safety precautions should be followed when handling the compound. It is for research use only and is not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
p-Hydroxyhippuric acid (PHHPA) is an N-acylglycine, a 4-hydroxy derivative of hippuric acid. It functions as a metabolite in human serum. Its function is related to N-benzoylglycine, which is the conjugate acid of PHHPA. PHHPA has been reported to be detected in both Drosophila melanogaster and Ginkgo biloba, and relevant data are available for reference.
4-Hydroxyhippuric acid (p-hydroxyhippuric acid) is an N-acylglycine and a 4-hydroxy derivative of hippuric acid. It is a by-product of polyphenol metabolism and increases microbiota activity associated with refeeding. It is a human serum metabolite associated with uremia and eosinophilic esophagitis. The compound is not approved for human use and is intended for research purposes only. It is available as a high-purity research reagent for laboratory use. Its role as a metabolite makes it a valuable tool for metabolic and clinical biomarker studies. |
| Molecular Formula |
C9H9NO4
|
|---|---|
| Molecular Weight |
195.17206
|
| Exact Mass |
195.053
|
| CAS # |
2482-25-9
|
| PubChem CID |
151012
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4g/cm3
|
| Boiling Point |
516.2ºC at 760mmHg
|
| Flash Point |
266ºC
|
| Vapour Pressure |
1.77E-11mmHg at 25°C
|
| Index of Refraction |
1.604
|
| LogP |
0.597
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
221
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZMHLUFWWWPBTIU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H9NO4/c11-7-3-1-6(2-4-7)9(14)10-5-8(12)13/h1-4,11H,5H2,(H,10,14)(H,12,13)
|
| Chemical Name |
2-[(4-hydroxybenzoyl)amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~512.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1237 mL | 25.6187 mL | 51.2374 mL | |
| 5 mM | 1.0247 mL | 5.1237 mL | 10.2475 mL | |
| 10 mM | 0.5124 mL | 2.5619 mL | 5.1237 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
